Prostate Cancer Progression:: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells

Olaniyi Ogundiya; Helen Whiteland; U. K. Shah; O. Bodger; J. Verma; C. Coker; H. Kynaston; S. Doak

doi:10.1016/j.ijsu.2018.05.725

Crynodeb

Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis.

Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting.

Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145.

Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression

Iaith wreiddiol	Saesneg
Tudalennau	S11-S12
Nifer y tudalennau	2
Dynodwyr Gwrthrych Digidol (DOIs)	https://doi.org/10.1016/j.ijsu.2018.05.725
Statws	E-gyhoeddi cyn argraffu - 02 Awst 2018
Digwyddiad	Association of Surgeons In Training International Surgical Conference 2018 - Edinburgh International conference Centre, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon Hyd: 06 Ebr 2018 → 08 Ebr 2018

Cynhadledd

Cynhadledd	Association of Surgeons In Training International Surgical Conference 2018
Teitl cryno	ASiT
Gwlad/Tiriogaeth	Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon
Dinas	Edinburgh
Cyfnod	06 Ebr 2018 → 08 Ebr 2018

NDC y CU

Mae’r allbwn hwn yn cyfrannu at y Nod(au) Datblygu Cynaliadwy canlynol

Mynediad at Ddogfen

10.1016/j.ijsu.2018.05.725

Cysylltiad parhaol

Dolen barhaus

Dyfynnu hyn

Ogundiya, O., Whiteland, H., Shah, U. K., Bodger, O., Verma, J., Coker, C., Kynaston, H., & Doak, S. (2018). Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells. S11-S12. Ffurflen grynodeb Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon. Cyhoeddiad ar-lein ymlaen llaw. https://doi.org/10.1016/j.ijsu.2018.05.725

@conference{7a0812005a374a5d89e14202ed3ecaea,

title = "Prostate Cancer Progression:: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells",

abstract = "Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis.Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting.Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145.Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression",

author = "Olaniyi Ogundiya and Helen Whiteland and Shah, {U. K.} and O. Bodger and J. Verma and C. Coker and H. Kynaston and S. Doak",

year = "2018",

month = aug,

day = "2",

doi = "10.1016/j.ijsu.2018.05.725",

language = "English",

pages = "S11--S12",

note = "Association of Surgeons In Training International Surgical Conference 2018, ASiT ; Conference date: 06-04-2018 Through 08-04-2018",

}

Ogundiya, O, Whiteland, H, Shah, UK, Bodger, O, Verma, J, Coker, C, Kynaston, H & Doak, S 2018, 'Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells', Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon, 06 Ebr 2018 - 08 Ebr 2018 tt. S11-S12. https://doi.org/10.1016/j.ijsu.2018.05.725

Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells. / Ogundiya, Olaniyi; Whiteland, Helen; Shah, U. K. et al.
2018. S11-S12 Ffurflen grynodeb Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, Teyrnas Unedig Prydain Fawr a Gogledd Iwerddon.

Allbwn ymchwil: Cyfraniad at gynhadledd › Crynodeb › adolygiad gan gymheiriaid

TY - CONF

T1 - Prostate Cancer Progression:

T2 - Association of Surgeons In Training International Surgical Conference 2018

AU - Ogundiya, Olaniyi

AU - Whiteland, Helen

AU - Shah, U. K.

AU - Bodger, O.

AU - Verma, J.

AU - Coker, C.

AU - Kynaston, H.

AU - Doak, S.

PY - 2018/8/2

Y1 - 2018/8/2

N2 - Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis.Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting.Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145.Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression

AB - Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis.Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting.Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145.Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression

U2 - 10.1016/j.ijsu.2018.05.725

DO - 10.1016/j.ijsu.2018.05.725

M3 - Abstract

SP - S11-S12

Y2 - 6 April 2018 through 8 April 2018

ER -

Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells